4/A: NEONC TECHNOLOGIES Director Alan Chiang Amends Beneficial Ownership Filing, Details Stock Grant and Warrant Exercise

NEONC TECHNOLOGIES HOLDINGS, INC. Director and 10% Owner Alan Chiang filed an amended Form 4, clarifying details of a cashless warrant exercise and reporting a grant of restricted common stock.

Summary

• Director and 10% Owner Ming-Fu (Alan) Chiang of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an amended Form 4 (Form 4/A) on June 5, 2025, to clarify previous beneficial ownership disclosures.
• The amendment specifically clarifies that a reported 'sale' of 56,250 shares of common stock at $25 per share was a result of a cashless exercise of a warrant to the Issuer, with no monetary consideration received by any party.
• On March 26, 2025, Mr. Chiang was granted 50,000 shares of restricted common stock under the Issuer's 2023 Equity Incentive Plan, which will vest 100% seven months after the effective date of the Issuer's initial Nasdaq listing.
• On the same date, HCWG LLC, in which Mr. Chiang holds a 37.5% indirect interest, exercised a warrant to purchase 312,500 shares of common stock at $12 per share on a cashless basis.
• As part of this cashless exercise, the Issuer withheld 150,000 warrant shares to cover the exercise price, resulting in 162,500 shares being issued to HCWG LLC.
• Mr. Chiang's indirect interest in the shares acquired through this warrant exercise was 117,188 shares, and his proportionate share of shares withheld for the cashless exercise was 56,250 shares.
• Other reported transactions include a transfer of 5,994 shares of common stock from HCWG LLC at a per share value of $18, and a disposal of 1,446 shares of common stock at $19.1299.
• Mr. Chiang also reported indirect beneficial ownership of 29,309 shares through Orion Biomed Inc., 888,148 shares through NeuCen Biomedical Co. Ltd. (partially owned by his spouse), and 488,196 shares through certain family members, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a factual report of insider transactions and beneficial ownership changes, with no explicit positive or negative commentary on company performance or outlook. The amendment clarifies a transaction, which is a neutral event in itself.

Positives

• The grant of 50,000 restricted common shares to Director Alan Chiang aligns his interests with shareholders and indicates a commitment to the company's long-term performance.
• The exercise of a warrant for 312,500 shares by HCWG LLC (in which Mr. Chiang has a significant interest) demonstrates confidence in the company's valuation at the $12 exercise price.

Negatives

• The cashless exercise of the warrant means the company did not receive cash proceeds from the exercise, as shares were withheld to cover the exercise price, potentially limiting immediate capital inflow.
• The disposal of 1,446 shares at $19.1299 and the transfer of 5,994 shares from HCWG LLC reduce the direct/indirect holdings of the reporting person.

Risks

• The complex structure of indirect beneficial ownership through entities like HCWG LLC, Orion Biomed Inc., NeuCen Biomedical Co. Ltd., and family members, while common, can introduce complexities in understanding full ownership and control.
• The cashless exercise mechanism, while beneficial for the warrant holder, means the company foregoes potential cash proceeds that could have been used for operations or growth initiatives.

Future Outlook

The 50,000 restricted common shares granted to Director Chiang are set to vest 100% seven months after the effective date of the Issuer's initial Nasdaq listing, indicating a future milestone for his full ownership of these shares.

Industry Context

This SEC Form 4/A filing is a routine disclosure of insider transactions and does not provide information on broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Transfer of shares and warrant exercise involving HCWG LLC, in which the reporting person has a 37.5% interest.
• Indirect beneficial ownership of shares held by Orion Biomed Inc., which is partly owned by the reporting person.
• Indirect beneficial ownership of shares held by NeuCen Biomedical Co. Ltd., which is partly owned by the reporting person's spouse.
• Indirect beneficial ownership of shares held by certain members of the reporting person's family.

Stakeholder Impact

• Shareholders: Changes in director's beneficial ownership, including a grant of restricted stock and transactions related to a warrant exercise, which can influence perceptions of insider confidence and potential future share supply.
• Company: The cashless warrant exercise means no direct cash inflow from this specific transaction, impacting the company's liquidity from this event.

Next Steps

• Vesting of 50,000 restricted common shares seven months after the effective date of the Issuer's initial Nasdaq listing.

Key Dates

Keywords

NEONC TECHNOLOGIES HOLDINGS, NTHI, SEC Form 4/A, Beneficial Ownership, Insider Trading, Director, Stock Grant, Warrant Exercise, Cashless Exercise, Restricted Stock, Equity Incentive Plan, Corporate Governance